Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors [Yahoo! Finance]
Maze Therapeutics, Inc. (MAZE)
Company Research
Source: Yahoo! Finance
SOUTH SAN FRANCISCO, Calif., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced the appointment of Hervé Hoppenot as Chairman of its Board of Directors, succeeding Charles Homcy, M.D., who will continue to serve on the Board. “I am honored to assume the role of Chairman of the Board at this pivotal moment for Maze Therapeutics,” said Mr. Hoppenot. “With encouraging first-in-human data for MZE782, an oversubscribed $150 million private placement, and important clinical milestones ahead, including the advancement of MZE829 targeting APOL1-mediated kidney disease, Maze is well-positioned to deliver meaningful progress. The team has consistently demonstrated strong execution, and I look forward to working with them to advance therapies that can transform the lives of patients with kidney and metabolic diseases.”
Show less
Read more
Impact Snapshot
Event Time:
MAZE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MAZE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MAZE alerts
High impacting Maze Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
MAZE
News
- Maze Therapeutics (NASDAQ:MAZE) was given a new $55.00 price target on by analysts at Wells Fargo & Company. They now have an "overweight" rating on the stock.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) had its "buy" rating reaffirmed by analysts at HC Wainwright.MarketBeat
- Maze Therapeutics, Inc. (MAZE) Presents at Jefferies London Healthcare Conference 2025 Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- Maze Therapeutics (NASDAQ:MAZE) was upgraded by analysts at Raymond James Financial, Inc. to a "strong-buy" rating.MarketBeat
- Maze Therapeutics (NASDAQ:MAZE) was downgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=MAZE&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall StreeMarketBeat
MAZE
Earnings
- 11/6/25 - Beat
MAZE
Sec Filings
- 12/4/25 - Form 144
- 11/21/25 - Form 4
- 11/21/25 - Form 144
- MAZE's page on the SEC website